Caplin Point Laboratories Limited

Equities

CAPLIPOINT

INE475E01026

Pharmaceuticals

Market Closed - Bombay S.E. 06:00:49 2024-04-26 am EDT 5-day change 1st Jan Change
1,350 INR -0.48% Intraday chart for Caplin Point Laboratories Limited +2.69% -0.42%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Caplin Point Arm Gets US FDA Final Nod for Ofloxacin Ophthalmic Solution MT
Caplin Point Unit Receives US FDA Nod for Eye Treatment Medication MT
Caplin Steriles Limited, A Subsidiary of Caplin Point Laboratories Limited Gets USFDA Approval for Ketorolac Tromethamine Ophthalmic Solution CI
Caplin Point Laboratories Arm Starts Operations of Oncology Facility at Kakkalur, India MT
Caplin One Labs Limited, a Wholly Owned Subsidiary of Caplin Point Laboratories Limited Successfully Completes New Oncology (Anti-Cancer) Facility, Commences Operations CI
Transcript : Caplin Point Laboratories Limited, Q3 2024 Earnings Call, Feb 09, 2024
Caplin Point Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Caplin Point Laboratories to Invest INR7 Billion in Tamil Nadu, India MT
Caplin Point Unit Gets US FDA Final Approval for Generic Ear Infection Drug MT
Caplin Point Laboratories Limited Announces Resignation of Hero Velladurai as President, R&D CI
Transcript : Caplin Point Laboratories Limited, H1 2024 Earnings Call, Nov 09, 2023
Caplin Point Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Caplin Point Laboratories Limited Approves Final Dividend for the Year Ended March 31, 2023 CI
Caplin Point Unit's Injectable and Ophthalmic Plant in India Gets VAI Classification from US FDA MT
Transcript : Caplin Point Laboratories Limited, Q1 2024 Earnings Call, Aug 08, 2023
Caplin Point Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Caplin Point Laboratories Limited Recommends Final Dividend for the Financial Year Ended March 31, 2023 CI
Caplin Point Laboratories to Incorporate Step-Down Subsidiary in US MT
Caplin Point Unit Gets US FDA Nod for Muscle Relaxant MT
Caplin Steriles Limited Gets United States Food and Drug Administration Approval for Cisatracurium Besylate Injection USP CI
Caplin Point Gets Four Observations from US FDA After Inspection of Injectable Unit at Gummidipoondi, India MT
Transcript : Caplin Point Laboratories Limited, Q4 2023 Earnings Call, May 27, 2023
Caplin Point Laboratories Limited Approves Interim Dividend for the Financial Year 2022-23 CI
Caplin Point Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023 CI
Caplin Point Laboratories Limited Announces Cessation of Rengaraj Viswanathan as Independent Director CI
Chart Caplin Point Laboratories Limited
More charts
Caplin Point Laboratories Limited is an India-based pharmaceutical company. The Company is engaged in producing, developing, and marketing a range of generic formulations and branded products and exporting to overseas markets. Its products include tablets, dry syrups (bottles), soft gels, capsules, suppositories, liquid syrups (bottles), liquid injectables in ampoules and vials, lyophilized vials, prefilled syringes (PFS), emulsion injection in ampoules and vials, ophthalmic droppers, pre-mix bags, topicals and sachets (liquids and powders). It also manufactures a range of ointments, creams, gels and lotions. Its principal research and development facilities are in Tamil Nadu, India. Its principal manufacturing facility is in Puducherry, India. It has presence in Latin America (LATAM), Southern Africa and Francophone Africa along with a presence in United States of America and European region. The Company’s subsidiaries include Caplin Point Far East Limited and Caplin Steriles Limited.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1,350 INR
Average target price
1,579 INR
Spread / Average Target
+16.95%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. CAPLIPOINT Stock
  4. News Caplin Point Laboratories Limited
  5. Caplin Point Laboratories Arm Starts Operations of Oncology Facility at Kakkalur, India